Phase 1 Combined Immunodeficiency Clinical Trials

4 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–4 of 4 trials

Recruiting

Phase 1Phase 2

Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

X-linked Severe Combined Immunodeficiency (XSCID)

National Institute of Allergy and Infectious Diseases (NIAID)40 enrolled1 locationNCT01306019

Recruiting

Phase 1Phase 2

Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)

Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency

Assistance Publique - Hôpitaux de Paris7 enrolled1 locationNCT05071222

Recruiting

Phase 1Phase 2

Autologous Gene Therapy for Artemis-Deficient SCID

Severe Combined Immunodeficiency

University of California, San Francisco24 enrolled1 locationNCT03538899

Recruiting

Phase 1

Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency

Severe Combined Immunodeficiency, X-Linked

Great Ormond Street Hospital for Children NHS Foundation Trust5 enrolled1 locationNCT03601286